Explore new website content that provides FAQs about the genomic testing process, the status of each treatment arm and its accrual, a patient eligibility overview, and more. Follow this link to the NCI-MATCH / EAY131 home page.
The Tomosynthesis Mammographic Imaging Screening Trial, known as TMIST or study EA1151, is a breast cancer screening trial of nearly 165,000 healthy women that is set to begin recruiting participants in the United States and Canada in the early fall of 2017. Follow this link to the new study information, which will expand over time.
With recent changes, Etta D. Pisano, MD (Beth Israel Deaconess Medical Center) now chairs the Early Detection, Diagnosis, and Surveillance Committee. The Cancer Control and Survivorship Committee added a Cardiotoxicity Working Group, and appointed Bonnie Ky, MD, MSCE (University of Pennsylvania) as chair. Follow this link for the updated organizational chart (downloadable).
The Cancer Letter: NCI-MATCH Keeps Enrolling (a series of three in-depth articles, including a Q&A with ECOG-ACRIN study chair, Keith T. Flaherty, MD)
Business Wire: Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer (PrECOG, LLC is part of this trial)
Clinical Oncology News: Consider Neoadjuvant Targeted Therapy for RCC (mentions the EA8143 aka PROSPER RCC trial; free registration required for access)
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD